Literature DB >> 1533734

Functional protein S in women with lupus anticoagulant inhibitor.

E Rossi1, L Gatti, D Guarneri, E Finotto, A Lombardi, L Preda.   

Abstract

Protein C (PC) and protein S (PS) are components of a potent, natural anticoagulant system. A deficiency of one of these two inhibitors is associated with thrombotic events in young people. A significant reduction in functional PS activity has been observed during normal pregnancy, and recurrent fetal loss may occur in women with lupus anticoagulant (LA) inhibitor. We measured functional PS activity and free PS antigen in 16 non pregnant patients with LA inhibitor and in 17 normal women as controls. A significant difference was observed between patients and controls in functional PS activity (65 +/- 23% vs 87 +/- 15%, p = 0.02) but not in free PS antigen (88 +/- 17% vs 93 +/- 17%). Functional PS activity decreased only in six patients (37%). Removal of IgG from plasma reduced the difference in functional PS activity between patients and controls. Immunologic IgG levels did not correlate with anti-phospholipid antibodies (APA) activities, activated partial thromboplastin time/kaolin clotting time (aPTT/KCT) data or functional PS activity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1533734     DOI: 10.1016/0049-3848(92)90245-6

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  2 in total

1.  Plasma concentrations of total/free and functional protein S are not decreased in systemic lupus erythematosus patients with lupus anticoagulant and/or antiphospholipid antibodies.

Authors:  J Matsuda; K Gohchi; M Gotoh; M Tsukamoto; N Saitoh
Journal:  Ann Hematol       Date:  1994-12       Impact factor: 3.673

2.  Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE.

Authors:  H Cohen; C J Doré; S Clawson; B J Hunt; D Isenberg; M Khamashta; N Muirhead
Journal:  Lupus       Date:  2015-05-04       Impact factor: 2.911

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.